Thus, our findings demonstrate that C14 and P8 have the potential to reduce the viability of breast cancer cell lines, with their primary efficacy against triple-negative and radioresistant cells and especially against the K-Ras4B mutant variants. The gene discussed is KRAS; the disease is breast carcinoma.